Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ARGENX SE (ARGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/05/2023 6-K Quarterly results
Docs: "FORM 6-K",
"argenx Reports First Quarter 2023 Financial Results and Provides Business Update - $218 million in first quarter VYVGART global net product sales - VYVGART received marketing authorization in Israel through partnership with Medison - 88 events achieved in ADHERE trial; topline data now expected in July 2023 - Enrollment completed in ADVANCE-SC and ADDRESS trials; topline data from both expected in fourth quarter of 2023 - Management to host conference call today at 2:30 pm CET Regulated Information/Inside Information May 4, 2023 Amsterdam, the Netherlands – argenx SE , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2023 financial results and provided a business update. “Throughout the first...",
"Investor Presentation"
05/05/2022 6-K Quarterly results
10/22/2020 6-K Quarterly results
Docs: "FORM 6-K",
"argenx Reports Third Quarter 2020 Financial Results and Provides Business Update - Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of 2020 - - Global Phase 3 ADDRESS trial evaluating subcutaneous efgartigimod in pemphigus patients on track to initiate by end of 2020 - - Decision to continue ADHERE trial beyond first 30 patients in chronic inflammatory demyelinating polyneuropathy now expected in first half of 2021 - - Management to host conference call today at 2:30 pm CEST - Breda, the Netherlands / Ghent, Belgium – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its financial results for ..."
05/14/2020 6-K Quarterly results
10/24/2019 6-K Quarterly results
05/09/2019 6-K Quarterly results
Docs: "6-K",
"argenx reports first quarter 2019 financial results and provides business update Breda, the Netherlands / Ghent, Belgium - argenx , a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the first quarter ended March 31, 2019. “During the first quarter, we advanced our broad clinical development plan of efgartigimod across four autoimmune indications in both our IV and subcutaneous formulations. Enrollment of our Phase 3 ADAPT clinical trial in generalized myasthenia gravis is on track, and we intend to launch a second Phase 3 program in primary immune thrombocytopenia in the second half of 2019 that will enco..."
10/25/2018 6-K Quarterly results
Docs: "6-K",
"argenx reports third quarter 2018 financial results and provides business update Breda, the Netherlands / Ghent, Belgium - argenx , a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the third quarter ended September 30, 2018. “The proof-of-concept data that we have generated in the last year from our Phase 2 clinical trials in generalized myasthenia gravis , immune thrombocytopenia and pemphigus vulgaris support efgartigimod's potential in severe autoimmune disease, and we are committed to advancing and expanding this clinical program as quickly as possible. We continue to see potential differentiation of..."
05/09/2018 6-K Quarterly results
Docs: "6-K",
"argenx announces results of Annual General Meeting of Shareholders",
"Voting Results from the Annual General Meeting of Shareholders held on May 8, 2018",
"argenx reports first quarter 2018 financial results and provides business update Breda, the Netherlands / Ghent, Belgium — argenx , a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the first quarter ended March 31, 2018. “We made excellent progress this quarter in executing on our pipeline strategy and are well-prepared for another milestone-rich year ahead in 2018. To start with our lead program efgartigimod , we presented the full data set from the Phase 2 clinical trial in myasthenia gravis at the American Academy of Neurology Annual Meeting showing a reduction in disease scores that correlated with o..."
10/26/2017 6-K Quarterly results
Docs: "6-K",
"argenx reports third quarter 2017 financial results and provides business update Breda, the Netherlands / Ghent, Belgium argenx , a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced financial results and provided a business update for the third quarter ended September 30, 2017. “We made strong progress during the third quarter launching the Phase 2 study of ARGX-113 in pemphigus vulgaris and delivering on our promise to expand the ARGX-113 program into new, carefully selected indications. With data readouts expected in 2018 from the Phase 2 studies in myasthenia gravis , immune thrombocytopenia and now PV, we will evaluate ARGX-113 in indications where diseas..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy